Electrostatic Potential Generated During Extracorporeal Pump Prime Circulation Before Cardiopulmonary Bypass Initiation

The development of electrostatic potentials generated during cardiopulmonary bypass (CPB) procedures using polyvinylchloride (PVC) tubing in conjunction with roller pumps has been previously documented. The resulting damage from the electrostatic discharge (ESD) has been reported to affect gas transfer devices, but details of potential damage to electronic components commonly used during extracorporeal circulation have not been similarly described. The purpose of this study was to measure the ability of a triboelectric potential to be generated from a primed, circulating, adult CPB pump before the initiation of CPB. Two identical adult CPB circuits were assembled: one incorporating a roller pump and the second incorporating a centrifugal pump mechanism. Primed pumps were circulated (1–6 LPM), and evidence of generated triboelectric potentials was evaluated using a digital multimeter (Fluke 8062 A). The ESD generated from an adult CPB circuit using a roller head configuration elicited a charge in excess of 600 DC V. An identical circuit constructed with a centrifugal pump mechanism did not produce any measurable charge. Sensitive electrical components in the CPB hardware platform may be damaged by ESD potential spikes of this magnitude. Preventative measures, such as circuit charge dissipation, may reduce the potential for such damage when using PVC tubing

Cardiopulmonary Bypass in a Patient with Factor XII Deficiency

The performance of cardiopulmonary bypass (CPB) in the factor XII-deficient patient is challenging in that the normal method for monitoring anticoagulation is ineffective as a result of an impaired contact activation system. We report the case of a factor XII-deficient patient who underwent surgical revascularization on CPB. His factor XII level was replenished with fresh-frozen plasma immediately before surgery. This management strategy lowered the baseline activated clotting time (ACT) to near normal, providing a meaningful ACT value for CPB. Factor XII is also a key component in the fibrinolytic system and its deficiency is associated with increased thrombosis. Because the factor XII level quickly returns to baseline postoperatively, perioperative care must include strategies to avoid postoperative thromboembolic events

Clinical Evaluation of a New In-Line Continuous Blood Gas Monitor

Two methodologies for obtaining accurate blood gas and electrolyte values during cardiopulmonary bypass (CPB) are traditional laboratory analyzers, which use an electrochemical technology, and continuous in-line monitoring systems, which use a fluorometric and/or spectrophotometric technology. The purpose of the present study was to evaluate the accuracy of a new continuous in-line monitor, the 3M™ CDI™ Blood Parameter Monitoring System 500, which provides continuous in-line measurements of pH, PCO2, PO2, potassium (K+), oxygen saturation, hematocrit, hemoglobin, and temperature, during partial or complete CPB. Study parameters included arterial pH, PCO2, PO2 , and K+ values. Overall performance was analyzed by calculating the mean difference (expressed as the bias) between the CDI system 500 and the laboratory analyzer for each parameter. The accuracy of the arterial pH, PCO2, and K+ values provided by the CDI system 500 was then evaluated using target values established in the acceptable performance standards for laboratory analyzers from the Clinical Laboratory Improvement Act of 1988 (CLIA '88). The accuracy of the PO2 value provided by the CDI system 500 was evaluated using a target value of ± 10% of the reference, or laboratory analyzer, value. A prospective multi-center trial was conducted following Institutional Review Board approval. A total of 75 cases was included in the analyses, with over 200 data points from 4 clinicallocations. Results for pH, PCO2 , and K+ were within the target values established by CLIA '88. pH bias was 0.00 ± 0.02 pH units. PCO2 bias was −0.3 ± 3.3 mm Hg. K+ bias was approximately + 0.12 ± 0.31 mmole/l. Results for PO2 were within 10% of the reference value. PO2 bias was 7.5 ± 13.8 mm Hg. The results of this clinical trial show that the CDI System 500 continuous in-line monitoring system provides values that meet the accuracy standards for laboratory analyzers for arterial pH, PCO2, PO2, and K+

Left Ventricular Assist Devices as Permanent Heart Failure Therapy: The Price of Progress

SUMMARY BACKGROUND DATA: The REMATCH trial evaluated the efficacy and safety of long-term left ventricular assist device (LVAD) support in stage D chronic end-stage heart failure patients. Compared with optimal medical management, LVAD implantation significantly improved the survival and quality of life of these terminally ill patients. To date, however, there have been no analyses of the cost related to the LVAD survival benefit. This paper addresses the cost of hospital resource use, and its predictors, for long-term LVAD patients. METHODS: Detailed cost data were available for 52 of 68 REMATCH patients randomized to LVAD therapy. We combined the clinical dataset with Medicare data, standard billing forms (UB-92), and line item bills provided directly by clinical centers. Charges were converted to costs by using the Ratio-of-Cost-to-Charges for each major resource category. RESULTS: The mean cost for the initial implant-related hospitalization was $210,187 ± 193,295. When implantation hospitalization costs are compared between hospital survivors and nonsurvivors, the mean costs increase from$159,271 ± 106,423 to $315,015 ± 278,713. Sepsis, pump housing infection, and perioperative bleeding are the major drivers of implantation cost, established by regression modeling. In the patients who survived the procedure (n = 35), bypass time, perioperative bleeding, and late bleeding were the drivers of cost. The average annual readmission cost per patient for the overall cohort was$105,326. CONCLUSIONS: The cost of long-term LVAD implantation is commensurate with other life-saving organ transplantation procedures like liver transplantation. As an evolving technology, there are a number of opportunities for improvement that will likely reduce costs in the future